NF-κB and the link between inflammation and cancer
- PMID: 22435567
- DOI: 10.1111/j.1600-065X.2012.01099.x
NF-κB and the link between inflammation and cancer
Abstract
The nuclear factor-κB (NF-κB) transcription factor family has been considered the central mediator of the inflammatory process and a key participant in innate and adaptive immune responses. Coincident with the molecular cloning of NF-κB/RelA and identification of its kinship to the v-Rel oncogene, it was anticipated that NF-κB itself would be involved in cancer development. Oncogenic activating mutations in NF-κB genes are rare and have been identified only in some lymphoid malignancies, while most NF-κB activating mutations in lymphoid malignancies occur in upstream signaling components that feed into NF-κB. NF-κB activation is also prevalent in carcinomas, in which NF-κB activation is mainly driven by inflammatory cytokines within the tumor microenvironment. Importantly, however, in all malignancies, NF-κB acts in a cell type-specific manner: activating survival genes within cancer cells and inflammation-promoting genes in components of the tumor microenvironment. Yet, the complex biological functions of NF-κB have made its therapeutic targeting a challenge.
© 2012 John Wiley & Sons A/S.
Similar articles
-
Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-kappaB-expressing and drug-resistant tumor cells.Mol Immunol. 2009 Apr;46(7):1340-50. doi: 10.1016/j.molimm.2008.11.014. Epub 2009 Jan 6. Mol Immunol. 2009. PMID: 19128834
-
Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential.Clin Sci (Lond). 2009 Mar;116(6):451-65. doi: 10.1042/CS20080502. Clin Sci (Lond). 2009. PMID: 19200055 Review.
-
NF-kappaB in cancer--a friend turned foe.Drug Resist Updat. 2004 Feb;7(1):53-67. doi: 10.1016/j.drup.2004.01.003. Drug Resist Updat. 2004. PMID: 15072771 Review.
-
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.J Natl Cancer Inst. 2011 Apr 20;103(8):645-61. doi: 10.1093/jnci/djr093. Epub 2011 Apr 4. J Natl Cancer Inst. 2011. PMID: 21464397
-
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):289-99. doi: 10.1007/s00005-011-0131-4. Epub 2011 May 28. Arch Immunol Ther Exp (Warsz). 2011. PMID: 21625848 Review.
Cited by
-
NF-κB1, NF-κB2 and c-Rel differentially regulate susceptibility to colitis-associated adenoma development in C57BL/6 mice.J Pathol. 2015 Jul;236(3):326-36. doi: 10.1002/path.4527. Epub 2015 Apr 21. J Pathol. 2015. PMID: 25727407 Free PMC article.
-
The NF-κB Signaling Pathway, the Microbiota, and Gastrointestinal Tumorigenesis: Recent Advances.Front Immunol. 2020 Jun 30;11:1387. doi: 10.3389/fimmu.2020.01387. eCollection 2020. Front Immunol. 2020. PMID: 32695120 Free PMC article. Review.
-
Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies.Biomedicines. 2024 Jan 16;12(1):201. doi: 10.3390/biomedicines12010201. Biomedicines. 2024. PMID: 38255306 Free PMC article. Review.
-
Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans.Crit Rev Toxicol. 2017 Jan;47(1):1-58. doi: 10.1080/10408444.2016.1206061. Epub 2016 Aug 18. Crit Rev Toxicol. 2017. PMID: 27537422 Free PMC article. Review.
-
miR146a-mediated targeting of FANCM during inflammation compromises genome integrity.Oncotarget. 2016 Jul 19;7(29):45976-45994. doi: 10.18632/oncotarget.10275. Oncotarget. 2016. PMID: 27351285 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources